CTG Pharma

Company Overview

Snapshot

Founded in January 2016 by Yoav Ben-Yaacov, Zelig Eshar, and Salomon Stemmer, CTG Pharma operates with 1-10 employees. The company secured seed funding in September 2018, with aMoon Fund participating. In September 2022, CTG Pharma ceased operations.

Business overview

CTG Pharma develops solutions for chimeric antigen receptor (CAR) T therapy, specifically targeting HER2-positive solid tumors while aiming to mitigate toxicity and on-target off-tumor reactions. The company's core technology includes a library of 65,000 promoters designed to enhance the safety and efficacy of human CAR T therapies by regulating CAR expression. This platform integrates unique signals from the solid tumor microenvironment for precise CAR expression, with initial product lines focused on HER2-positive cancers. CTG Pharma operates within the Health Tech & Life Sciences sector, serving the Pharmaceuticals market.

Company Intelligence Q&A

What is CTG Pharma's primary focus?

CTG Pharma focuses on enabling therapeutic applications of Chimeric Antigen Receptor (CAR) T cells in solid tumors, aiming to enhance safety and efficacy by mitigating toxicity and on-target off-tumor reactions.

When was CTG Pharma founded and by whom?

CTG Pharma was founded in January 2016 by co-founders Yoav Ben-Yaacov, Zelig Eshar, and Salomon Stemmer.

What is the status of CTG Pharma?

CTG Pharma ceased to operate in September 2022.

What was the company's last known funding event?

CTG Pharma secured seed funding in September 2018, with aMoon Fund participating.

What is CTG Pharma's core technology?

CTG Pharma's core technology involves a rationally designed library of 65,000 different switches (promoters) that enable safer CAR T therapy by regulating CAR expression specifically in the tumor microenvironment, minimizing immune response in healthy tissues.